For many users, GLP-1 drugs are not a long-term commitment but rather a step along the way in their weight loss or wellness journey
Significant effects of HM11260C (efpeglenatide) on body weight over 20 weeks in obese subjects without diabetes: a randomised, double-blind, placebo controlled study [abstract]
The most pronounced differences were observed in gastrointestinal and metabolic events: nausea (combination: n = 9651 vs monotherapy: n = 38,030), vomiting (4383 vs 17,062), pancreatitis (1389 vs 6655), and hypoglycemia (773 vs 1778)
By contrast, real-world persistence drops off a cliff fairly early on
This compound is supplied strictly for laboratory research purposes only
Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality and renal outcomes in patients with diabetes and albuminuria: a systematic review and meta-analysis